Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

Seneque

Status

Completed

Conditions

Healthy Volunteers

Treatments

Dietary Supplement: Nicotinamide mononucleotide (NMN-C)

Study type

Interventional

Funder types

Industry

Identifiers

NCT04862338

C1677

Details and patient eligibility

About

The purpose of this study is to evaluate the physiological and/or biological actions of nicotinamide mononucleotide (NMN-C) in healthy adults receiving a repeated-dose over the course of 28 days by studying the tolerance and pharmacodynamics of this product.

Enrollment

17 patients

Sex

All

Ages

30 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers should be

Men between the ages of 30 and 60 years old
With a BMI between 23 and 30 kg/m2
With a weight > or = 70kg
Giving their free informed consent to the study

Exclusion criteria

May not be included in the study Volunteers with

a history of allergy to vitamin B3 (niacin or nicotinamide)
immunocompromised or suffering from a serious or progressive disease (cardiac, pulmonary, hepatic, renal, hematologic, neoplastic or infectious)
with abnormal results on the screening bioassay (CBC, Transaminases (AST, ALT, GGT), Bilirubin, Creatinine, CPK, Ionogram, Blood glucose, Hba1c, Lipid profile)
having donated blood in the month preceding inclusion,
having consumed more than 2 glasses of alcohol per day,
being under medication or taking food supplements,
having reached the maximum compensation threshold for research involving the human being as provided for by the regulations or having participated in another biomedical research project that required blood samples in the previous month,
involved in another clinical trial or being in the exclusion period of a previous clinical trial.